

Human Cardiac Development and Regeneration Modeling

Sheila Moffitt Mason*

Southern Utah University, 351 W University Blvd, Cedar City, UT 84720, USA

*: All correspondence should be sent to: Dr. Sheila Moffitt Mason

Author's Contact: Dr. Sheila Moffitt Mason, Ph.D., E-mail: smmason@aol.com

DOI: <https://doi.org/10.15354/si.24.re1039>

Funding: No funding source declared.

COI: The author declares no competing interest.

AI Declaration: The author affirms that artificial intelligence did not contribute to the process of preparing the work.

Human cardiac development and regeneration modeling are crucial areas of research that hold immense promise for advancing regenerative medicine and treating cardiovascular diseases. Understanding the intricate process of cardiac development, from the formation of the primitive heart tube to the maturation of the fetal heart, provides insights into potential therapeutic strategies for cardiac regeneration. This article explores the key stages of cardiac development, factors influencing cardiac regeneration, current models for studying regenerative processes, challenges and opportunities in regenerative medicine, future directions in cardiac development research, clinical applications of regenerative modeling, and the implications for healthcare. By delving into these aspects, researchers and healthcare professionals can gain a deeper understanding of how to harness the regenerative potential of the human heart for improved patient outcomes.

Keywords: Human Heart; Cardiac Development; Regeneration; Modeling; Therapeutics

Science Insights, 2024 August 31; Vol. 45, No. 2, pp.1465-1474.

© 2024 Insights Publisher. All rights reserved.



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the [Creative Commons Attribution-NonCommercial 4.0 License](https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed by the Insights Publisher.

Introduction

THE PROCESS of human cardiac development is intricate and highly regulated, and it commences during the early stages of embryonic development (1). The heart is the initial organ to develop and function, and it is crucial for the maintenance of life. Precursor cells migrate to the location where the heart will develop, differentiate into specialized cell types, and commence to beat rhythmically during the initial weeks of gestation (2). This process is regulated by a precise sequence of genetic and molecular cues that assure the proper

alignment of cardiac structures, regulate cell proliferation, and determine cell fate. Congenital heart defects are among the most prevalent birth abnormalities, affecting approximately 1% of infants worldwide, that can result from the disruption of these complex mechanisms (3, 4). In order to enhance patient outcomes and develop potential therapeutics for cardiovascular disorders, it is essential to comprehend the molecular pathways that are involved in human cardiac development.

The ultimate objective of cardiac regeneration is to enhance cardiac function and prevent heart failure by restoring




Figure 1. Development of Human Heart.

damaged heart tissue through a variety of therapeutic approaches (5). This emerging discipline has the potential to treat a diverse array of cardiovascular diseases, such as cardiomyopathy and myocardial infarction, which are the primary causes of morbidity and mortality on a global scale. In order to facilitate cardiac regeneration, numerous strategies have been examined, including tissue engineering, gene therapy, and stem cell therapy. Stem cells that are derived from sources such as bone marrow or the heart have demonstrated the ability to regenerate cardiac tissue by differentiating into new heart cells or fostering repair processes. The objective of gene therapy is to deliver specific genes that will either enhance the regenerative capacity of heart cells or modulate inflammatory responses following an injury. Tissue engineering techniques entail the development of biomimetic scaffolds that can facilitate cell growth and differentiation in heart-damaged regions. Ultimately, cardiac regeneration initiatives have the potential to revolutionize cardiovascular medicine by offering innovative remedies for heart conditions that are debilitating.

Embryonic Heart Development

Key Stages of Cardiac Development

Early in embryogenesis, the mesoderm layer of cells in the embryo establishes a linear structure known as the primitive heart tube, which is the initial critical phase of human cardiac development. The primitive heart tube subsequently begins to loop and segment, resulting in the formation of the heart's chambers and primary blood vessels (6) (**Figure 1**). This stage is essential for the establishment of the heart's fundamental structure and the establishment of the groundwork for more advanced development.

The subsequent phase of human cardiac development entails the differentiation of the primitive heart tract into the four

chambers of the heart: the left and right atria, as well as the left and right ventricles. This process is regulated by a series of intricate genetic and molecular signaling pathways that regulate the expression of specific genes in the developing heart cells. Abnormalities in heart development, such as septal defects or valve malformations, may result from any disruptions in these pathways.

The cardiac septa, which divide the heart into distinct left and right portions, are the next critical stage of cardiac development after the chambers have formed (7). To prevent the mingling of oxygen-rich and oxygen-poor blood, the septa are composed of specialized cells that migrate and fuse together to form the physical barriers between the chambers. Serious congenital heart defects, such as atrial or ventricular septal defects, can be the consequence of improperly forming the cardiac septa.

The subsequent phase is the establishment of the coronary circulation, which provides blood to the myocardium of the heart muscle, following the formation of the cardiac septa. The coronary arteries are derived from the aorta and expand into the developing heart to provide oxygen and sustenance to the developing tissues (8). Myocardial infarction or other cardiac complications may result from any disruptions in coronary artery development, which can result in reduced blood flow to the heart muscle.

The heart valves, which regulate the passage of blood between the chambers of the heart, are the next critical stage of cardiac development as the heart continues to mature and grow. The leaflets and cusps of the valves are formed by specialized cells known as valvular interstitial cells, which differentiate (9). Proper valve formation is crucial for the prevention of reflux of blood, which can result in valve stenosis or regurgitation, and the maintenance of normal blood flow.

The establishment of the conduction system is another critical phase of human cardiac development. This system is

responsible for coordinating the rhythmic contraction of the heart muscle in order to effectively pump blood. The atria and ventricles' contractions are synchronized by the conduction system, which is composed of specialized cells that generate electrical impulses and transmit them through the heart (10). Arrhythmias or other cardiac rhythm disorders can be life-threatening if not properly managed as a result of disruptions in the conduction system.

The heart undergoes additional growth and maturation in order to accommodate the fetus's growing needs during the later phases of human cardiac development. As the myocardium of the heart muscle thickens and strengthens, it enables the heart to circulate oxygen and nutrients throughout the body and pump blood more efficiently (11). The heart's electrical and mechanical properties are also being refined to ensure that it can continue to function properly and adjust to the evolving requirements of the developing embryo.

The fetal heart undergoes a process known as remodeling in the final phases of human cardiac development to prepare for the transition from fetal to neonatal circulation after birth (12). This remodeling process entails modifications to the structure and function of the heart valves, septa, and blood vessels to accommodate the increased blood flow and oxygenation that occurs following birth. Complications in the transition to postnatal circulation and an elevated risk of neonatal cardiac abnormalities may result from any disruptions in this remodeling process.

Maturation of the Fetal Heart

The development of the heart chambers is a significant milestone in the growth of the fetal heart. At the conclusion of the initial trimester, the four chambers of the heart, namely the left and right atria and ventricles, are completely developed and operational (1). This facilitates the adequate flow of blood through the fetal heart, guaranteeing the delivery of oxygen and nutrients to the developing fetus.

Another vital component of embryonic heart maturation is the formation of the heart valves. Cardiac valves are essential for controlling the circulation of blood within the heart and preventing the reverse flow of blood (9). In the second trimester, the valves start to develop and become fully functional, allowing the proper flow of blood through the heart and out to the body.

During the process of fetal growth and development, the size and form of the fetal heart also experiences alterations. The size of the heart increases in direct correlation to the overall size of the body, as the chambers of the heart expand to accommodate the greater amount of blood being circulated (13). The morphology of the heart also undergoes transformation, assuming a more analogous structure to the fully developed heart observed in adults.

Another crucial factor in the maturation of the fetal heart is the formation of the electrical system that regulates the heart-beat. The autonomous pulsation of the fetal heart commences in the initial stages of pregnancy, approximately at 3-4 weeks of gestation. During pregnancy, the cardiac electrical system undergoes maturation, which guarantees regular and efficient heartbeats, facilitating the circulation of blood throughout the body (10).

Factors Influencing Cardiac Regeneration

Role of Stem Cells in Cardiac Regeneration

Mesenchymal stem cells (MSCs) are a primary type of stem cells employed in cardiac regeneration. MSCs possess the capacity to undergo differentiation into a range of cell types, such as cardiomyocytes, endothelial cells, and smooth muscle cells. When introduced into the injured cardiac tissue, MSCs could stimulate the development of fresh blood vessels and enhance cardiac performance (14). Studies have demonstrated that MSCs have the ability to decrease inflammation and scarring in the heart, resulting in enhanced results for individuals suffering from cardiac ailments (15, 16).

Induced pluripotent stem cells (iPSCs) are another form of stem cells utilized in the process of cardiac regeneration. iPSCs are created through the process of reprogramming mature cells, such as skin cells, to acquire the ability to differentiate into any cell type. These cells possess the capacity to undergo differentiation into every cell type found in the body, including cardiomyocytes. iPSCs present a highly promising strategy for cardiac regeneration due to their ability to be tailored to individual patients and circumvent the risk of immunological rejection (17). Nevertheless, before iPSCs can be applied in clinical practice, it is crucial to tackle obstacles like the potential for tumor formation and the requirement for effective differentiation regimens (18).

Embryonic stem cells (ESCs) are currently under investigation for their possible role in cardiac regeneration. ESCs originate from the inner cell mass of the blastocyst and possess the capacity to undergo differentiation into any cell type found in the body. Studies have demonstrated that cardiomyocytes produced from ESCs can integrate into injured heart tissue and enhance cardiac function in animal models (19, 20). Nevertheless, the utilization of ESCs in clinical applications is restricted due to ethical considerations and the potential for immunological rejection (21).

Aside from stem cell transplantation, studies are also investigating methods to stimulate the movement of existing stem cells within the body and boost their ability to regenerate cardiac tissue for the purpose of cardiac regeneration (22, 23). For instance, granulocyte colony-stimulating factor (G-CSF) can stimulate the movement of stem cells produced from the bone marrow to the heart, so enhancing the process of cardiac repair (24, 25). Likewise, the use of small chemicals and growth factors can stimulate the growth and specialization of naturally occurring cardiac stem cells, resulting in enhanced heart function (26, 27).

Although preclinical studies have shown promising results, the use of stem cell treatment for cardiac regeneration is hindered by various hurdles that must be resolved prior to its general clinical implementation. A primary obstacle is the limited viability and successful integration of transplanted stem cells into the hostile microenvironment of the compromised cardiac tissue (28). Efforts are underway to develop strategies aimed at enhancing cell survival, including the use of growth factors to condition cells or the modification of cells to enhance their resistance to oxidative stress (29). One additional obstacle is the potential for arrhythmias and tumors that are linked to the trans-

plantation of stem cells into the heart (30). Studies have demonstrated that when stem cells are transplanted, they are capable of establishing electrical connections with the existing heart muscle cells of the recipient and can cause irregular heart rhythms, known as arrhythmias (30, 31). Researchers are currently exploring methods to reduce the occurrence of irregular cardiac rhythms in stem cell therapy for the heart. One approach being studied involves the use of cell-specific stimulators to regulate the contractions of transplanted cells, with the aim of enhancing the safety of this therapy.

Influence of Growth Factors and Cytokines

Growth factors are a type of signaling molecules that play a crucial role in controlling the growth and development of cells. Growth factors, including transforming growth factor-beta (TGF- β), fibroblast growth factor (FGF), and insulin-like growth factor (IGF), are crucial in cardiac regeneration as they stimulate the expansion and specialization of cardiac stem cells and progenitor cells (32). These growth factors initiate distinct cellular signaling pathways that control the expression of genes and stimulate the progression of the cell cycle, resulting in the generation of fresh cardiac muscle cells.

Additionally, cytokines are tiny proteins that govern immune responses and inflammation. Cytokines, including interleukin-10 (IL-10), IL-6, and tumor necrosis factor-alpha (TNF- α), are essential in cardiac regeneration as they regulate the inflammatory response and facilitate tissue repair. Cytokines have a crucial role in controlling the movement of immune cells to the location of an injury, stimulating the generation of growth factors and proteins that make up the extracellular matrix, and facilitating the formation of new blood vessels and restructuring of tissues (33, 34).

Moreover, growth factors and cytokines engage in intricate interactions within a network of signaling pathways to facilitate the regeneration of the heart. For instance, growth factors like FGF and vascular endothelial growth factor (VEGF) induce the synthesis of cytokines such as IL-6 and TNF- α , which subsequently enhance the activation and differentiation of cardiac stem cells and progenitor cells (35). The interaction between growth factors and cytokines is crucial for synchronizing the many cellular processes associated with cardiac regeneration.

Furthermore, growth factors and cytokines can be administered to the location of cardiac damage using many therapeutic approaches, including gene therapy, stem cell transplantation, and delivery methods based on biomaterials. Researchers can augment the healing ability of the heart and stimulate the creation of new cardiac muscle cells by administering growth factors and cytokines directly to the injured heart tissues (36). This method has significant potential for treating patients suffering from heart failure and other cardiovascular ailments.

Furthermore, the regulation and functioning of growth factors and cytokines are disrupted in individuals suffering from heart failure and other cardiovascular disorders. Patients with severe heart failure exhibit reduced levels of FGF and VEGF, which hampers the ability of the heart to regenerate and repair damaged tissue (37). Researchers are seeking to restore normal cardiac function and enhance the quality of life for patients with

cardiovascular illnesses by specifically addressing these growth factors and cytokines using innovative treatment methods.

New breakthroughs in regenerative medicine and stem cell technologies have allowed scientists to create innovative methods for improving the process of cardiac regeneration. Researchers have effectively developed cardiac patches and scaffolds that release growth factors and cytokines to stimulate the repair of injured heart tissues (38). Researchers aim to enhance the effectiveness of cardiac regeneration and the restoration of normal heart function by integrating biomaterials-based delivery systems with stem cell therapy.

Moreover, the advancement of small molecule medicines and biologics that selectively target growth factors and cytokines holds the potential to completely transform the area of cardiac regeneration. The development of innovative treatments could improve the heart's ability to regenerate and repair tissue by identifying important signaling pathways and molecular targets involved in cardiac regeneration. These novel strategies show significant potential for managing individuals with heart failure and other cardiovascular disorders.

Also, the utilization of growth factors and cytokines, in conjunction with other therapeutic approaches like cardiac rehabilitation and lifestyle adjustments, might augment the heart's regenerative ability and boost the overall clinical results for patients with cardiovascular disorders. Researchers can enhance the treatment benefits and prognosis for patients with heart failure and other cardiovascular disorders by using a multidisciplinary approach that focuses on several elements of cardiac regeneration.

Models for Studying Cardiac Regeneration

Animal Models for Cardiac Regeneration

Animal models offer researchers valuable insights into the intricate biological processes that are involved in cardiac regeneration. Scientists can develop a more comprehensive comprehension of the process by which cardiac tissue regenerates after being injured by investigating the regenerative capabilities of animal hearts. This information is crucial for the creation of novel therapies that can promote the regeneration of damaged cardiac tissue in humans.

The mouse is a widely used animal model in cardiac regeneration research. Mice are an excellent choice for laboratory research on heart regeneration due to their brief reproductive cycle, ease of handling, and relatively small size. Researchers have been able to develop transgenic mice with specific mutations in genes that regulate cardiac regeneration, which has facilitated the study of the molecular mechanisms involved in this process, thanks to recent advancements in genetic engineering (39).

The zebrafish is another animal model that is frequently employed in cardiac regeneration research. Zebrafish are an invaluable model for the study of the cellular and molecular mechanisms of cardiac regeneration due to their extraordinary capacity to regenerate their hearts following injury (40, 41). The regeneration process can be observed and studied in real time by




Figure 2. Models of Cardiac Regeneration.

researchers using sophisticated imaging techniques, as zebrafish embryos are transparent.

Pigs are also employed as animal models in cardiac regeneration research due to their physiological similarities to humans. Pigs are a valuable model for the testing of novel therapies for heart diseases due to their similar cardiac anatomy and function to humans (42). In comparison to mice and zebrafish, piglets have a larger heart size, which enables researchers to investigate the effects of cardiac regeneration on a more clinically relevant scale.

Before potential cardiac regeneration therapies can be tested in human clinical trials, they must be assessed for safety and efficacy using animal models. Researchers can evaluate the therapeutic effects of new pharmaceuticals, stem cell therapies, and other interventions on cardiac function and regeneration by employing animal models. Additionally, animal models enable researchers to examine the potential risks and adverse effects of these therapies, which is invaluable information for the development of human clinical trials.

Animal models are crucial in cardiac regeneration research; however, their utilization is hindered by constraints and obstacles. The translatability of research findings to clinical practice may be restricted by the fact that animal models may not completely replicate the complex pathophysiology of human heart diseases. Furthermore, the use of animal models in research must be guided by precise guidelines for the humane treatment and welfare of animals, as ethical considerations and regulatory requirements must be considered.

Researchers are investigating novel animal models to investigate cardiac regeneration as our comprehension of the process continues to develop. For instance, non-human primates have become an invaluable paradigm for the investigation of cardiac regeneration as a result of their genetic and physiologi-

cal similarities to humans (43). A prospective model for translational research in cardiac regeneration, non-human primates provide a more accurate representation of human heart diseases and responses to therapies (Figure 2).

In vitro Models for Cardiac Regeneration

The capacity to replicate the intricate microenvironment of the heart is one of the primary benefits of employing in vitro models in cardiac regeneration research. The effects of various growth factors and signaling pathways, the responses of cardiac cells to different stimuli, and the interactions between distinct cell types can all be investigated using these models. Researchers can devise novel strategies for the regeneration of cardiac tissue and the healing of damaged heart tissue by comprehending these mechanisms.

In vitro models also provide a high degree of control over experimental conditions, enabling researchers to manipulate variables such as cell types, culture conditions, and growth factors (44). Researchers are able to investigate specific aspects of cardiac regeneration in isolation, as this level of control eliminates the confounding factors that are present in in vivo models. Furthermore, in vitro models are frequently utilized for high-throughput screening of potential therapeutic agents due to their cost-effectiveness and reduced time commitment in comparison to animal studies.

The utility of in vitro models for cardiac regeneration research has been further enhanced by recent advancements in tissue engineering techniques. For instance, researchers have created bioengineered cardiac tissue constructs that closely resemble the structure and function of native heart tissue (45). These constructs can be employed to investigate the regenerative potential of various cell types and to evaluate the efficacy of innovative therapies for cardiac diseases.

The use of iPSCs is another significant development in the field of *in vitro* cardiac regeneration research. These cells can be reprogrammed to differentiate into cardiac cells by utilizing a patient's own epidermis cells. iPSC-derived cardiac cells can be employed to model patient-specific cardiac diseases, investigate the mechanisms that underlie these diseases, and evaluate personalized therapies for heart regeneration (46).

In vitro models for cardiac regeneration research have certain limitations, despite their numerous advantages. For instance, these models may not accurately represent the intricacy of the *in vivo* environment, which encompasses factors such as the immune response, blood flow, and the extracellular matrix. In addition, the behavior of cardiac cells in living organisms may not be faithfully represented by cell culture systems, which are susceptible to artifacts.

Researchers are increasingly employing multi-cellular *in vitro* models that incorporate a variety of cell types, including cardiomyocytes, fibroblasts, and endothelial cells, to overcome some of these constraints. These models offer a more physiologically pertinent platform for the study of cardiac regeneration by more closely simulating the cell-cell interactions and tissue architecture of the heart. Furthermore, the relevance of *in vitro* models for cardiac regeneration research is further enhanced by the development of microfluidic devices that can replicate the dynamic mechanical and biochemical stimuli found in the heart (Figure 2).

Three-Dimensional Tissue Engineering for Cardiac Regeneration

The process of three-dimensional (3D) tissue engineering for cardiac regeneration research entails the use of specialized materials and techniques to produce 3D structures that closely resemble the structure and function of natural heart tissues (47). These 3D tissue constructs can be employed to investigate the behavior of heart cells in a more realistic and controlled environment, thereby offering valuable insights into the mechanisms of cardiac regeneration and potential treatment strategies for heart diseases. Researchers can gain a more comprehensive understanding of the way in which heart cells respond to a variety of stimuli and medications by developing 3D tissue models that accurately replicate the intricate microenvironment of the heart. This will result in more effective and personalized therapies for cardiac patients.

The capacity to generate patient-specific tissue constructs that closely resemble the individual's distinctive heart anatomy and physiology is one of the primary benefits of 3D tissue engineering in cardiac regeneration research. Researchers have the potential to enhance the success rates of cardiac regeneration therapies by creating personalized treatment approaches that are more tailored to the specific requirements of each patient by utilizing a patient's own cells to construct 3D tissue models. This personalized approach also reduces the risk of immune rejection and other complications that may result from the use of foreign or donor cells in tissue engineering procedures.

3D tissue engineering for cardiac regeneration research enables the integration of a variety of biomaterials and growth factors, which can improve the regenerative capacity of the heart tissue, in addition to the development of personalized tissue

constructs. These biomaterials have the potential to stimulate the formation of new blood vessels, promote cell growth and differentiation, and provide structural support in the damaged cardiac tissue. Researchers can develop more durable and functional tissue replacements that can more effectively integrate with the adjacent heart tissues and enhance heart function in cardiac patients by engineering 3D tissue constructs with these bioactive materials.

The study of the role of stem cells in heart regeneration and restoration is made possible by 3D tissue engineering for cardiac regeneration research. Stem cells have demonstrated significant potential in the regeneration of damaged heart tissues, as they possess the distinctive capacity to differentiate into a variety of cell types, including cardiac muscle cells. Researchers can explore the mechanisms by which stem cells contribute to heart regeneration and develop innovative stem cell-based therapies for treating cardiac diseases by incorporating them into 3D tissue constructs (48). This research has the potential to facilitate the development of more sophisticated treatments for heart failure and other cardiovascular conditions, as well as to result in novel discoveries in cardiac regeneration.

3D tissue engineering can be employed to investigate the impact of genetic mutations and diseases on the development and function of the heart in the context of cardiac regeneration research. Researchers can gain valuable insights into the underlying mechanisms of inherited heart disorders and potential treatment options by constructing 3D tissue models that contain specific genetic abnormalities or disease conditions. The models can be used to investigate the impact of these factors on the behavior and function of heart cells. This information has the potential to enhance our comprehension of genetic cardiac diseases and advance the development of targeted therapies that target the underlying causes of these conditions.

In addition, the field of drug discovery and development has the potential to be transformed by the application of 3D tissue engineering to cardiac regeneration research, which will enable the development of more precise and predictive models for the evaluation of novel drugs and treatments. By employing 3D tissue constructs that closely resemble natural cardiac tissues, researchers can assess the efficacy and safety of potential drug candidates in a more physiologically relevant environment, thereby reducing the dependence on animal models and expediting the drug development process. This method has the potential to enhance the success rates of clinical trials for cardiac medications and identify new therapeutic agents for heart diseases.

Moreover, 3D tissue engineering for cardiac regeneration research presents novel opportunities for organ replacement and tissue transplantation in the field of regenerative medicine. Researchers can generate tissue implants that can be transplanted into patients with damaged or failing hearts by engineering functional and vascularized 3D tissue constructs that closely resemble natural heart tissues. This offers a potential alternative to heart transplantation. These tissue-engineered constructs have the potential to enhance heart function, decrease the risk of rejection, and provide a more sustainable solution for treating end-stage heart failure in patients who are not eligible for traditional heart transplants (Figure 2).

Future Directions in Cardiac Regeneration Research

Gene Editing Technologies

The targeting of genes involved in cell proliferation and differentiation is one of the primary applications of gene editing technologies in cardiac regeneration. Scientists have the potential to enhance the capacity of cardiac cells to regenerate and repair damaged tissue by modifying these genes. The regenerative capacity of the heart may be improved through the targeted modification of genes such as GATA4 and Mef2c, which have been demonstrated to play significant roles in cardiac development and regeneration (49).

Gene editing technologies can also be employed to alter the immune response to heart injury, in addition to targeting specific genes involved in cardiac regeneration. The immune system is essential for the recovery process following a heart attack or other cardiac event; however, an overactive immune response can also result in tissue injury (50). We can enhance the efficiency of healing and decrease the likelihood of complications by utilizing gene editing to regulate the immune response.

The utilization of stem cells to replace damaged heart tissue is an additional thrilling application of gene editing in cardiac regeneration. Stem cells possess an extraordinary capacity to differentiate into a variety of cell types, such as cardiac muscle cells. The differentiation of stem cells into functional cardiac tissue can be realized by modifying their genes through gene editing technologies (51). This method has the potential to revolutionize the treatment of cardiac diseases by offering a sustainable source of new heart cells for transplantation.

Also, genetic mutations that contribute to cardiac diseases can be repaired through the use of gene editing technologies. Cardiac disease that is inherited, such as hypertrophic cardiomyopathy, has been associated with mutations in genes like MYBPC3 and TNNT2 (52). Potentially, the development of these devastating conditions can be prevented and even reversed by utilizing gene editing to rectify these mutations in patient-specific cells.

Gene editing technologies are also promising for the development of personalized medicine in cardiac regeneration, in addition to their potential in treating heart diseases. Specific genetic factors that may affect an individual's response to treatments for heart diseases could be identified by examining their genetic composition. By employing gene editing to target these factors, personalized therapies can be created that are customized to the distinct genetic profile of each patient, potentially resulting in more effective and safer treatments (53). It is vital to acknowledge that gene editing technologies have the potential to revolutionize myocardial regeneration; however, there are also ethical and safety concerns that must be resolved. The potential for unintended genetic alterations and the long-term effects of these modifications are concerns that arise with the use of gene editing in humans (54, 55). Furthermore, the off-target effects of gene editing technologies can pose a threat to patient safety and necessitate meticulous monitoring and mitigation.

Personalized Approaches to Cardiac Regener-

ation

Personalized cardiac regeneration strategies are characterized by the customization of treatment strategies to the distinctive genetic, molecular, and physiological characteristics of each individual. Clinicians can create targeted therapies that address specific deficiencies or abnormalities in the patient's cardiovascular system by comprehending the underlying causes of an individual's cardiac condition (56). In contrast to conventional one-size-fits-all treatment approaches, this personalized approach can result in more sustainable and effective outcomes for patients.

The utilization of stem cell therapies is one of the fundamental principles of personalized cardiac regeneration strategies. Stem cells possess the distinctive capacity to differentiate into a variety of cell types within the body, such as cardiac muscle cells. Clinicians can repair damaged cardiac tissue and restore heart function by utilizing the regenerative potential of stem cells. The development of innovative stem cell-based therapies that exhibit promising results in preclinical and clinical studies has been facilitated by recent advancements in stem cell research (57).

The utilization of tissue engineering methodologies is an additional critical component of personalized cardiac regeneration strategies. Using a combination of cells, biomaterials, and growth factors, tissue engineering is the process of generating functional, living tissues. Clinicians can offer patients personalized treatment options that facilitate the regeneration of damaged cardiac tissue by creating custom-made cardiac tissues that closely resemble the structure and function of natural heart tissue (58). This method has the potential to significantly enhance the outcomes of patients with heart failure, myocardial infarction, and other cardiovascular conditions.

Gene therapies are also employed in personalized approaches to cardiac regeneration, in addition to stem cell therapies and tissue engineering techniques. Gene therapy entails the introduction of therapeutic genes into the body to rectify genetic defects or regulate gene expression. The overall function of the heart could be enhanced by targeting specific genes that are essential for cardiac regeneration and repair. This approach promotes the development of new blood vessels, stimulates the proliferation of cardiac muscle cells, and enhances cardiac function (59). Gene therapy has the potential to be a highly effective personalized treatment option for patients with genetic cardiac disorders and other cardiovascular conditions.

The significance of lifestyle and environmental factors in influencing heart health is also considered in personalized approaches to cardiac regeneration. Clinicians can assist patients in establishing healthier behaviors that promote cardiac regeneration and overall cardiovascular health by addressing lifestyle factors such as diet, exercise, smoking, and stress management. Heart function and repair processes can also be influenced by environmental factors, including pollution, pollutants, and radiation exposure. Clinicians can facilitate the success of personalized cardiac regeneration therapies by reducing exposure to these detrimental factors and fostering a healthy living environment.

It is crucial to acknowledge that personalized approaches to cardiac regeneration are still in the early phases of develop-

ment and may encounter obstacles in regulatory approval, cost-effectiveness, and scalability. Nevertheless, these challenges are being surmounted by ongoing research endeavors and technological advancements, which are bringing personalized cardiac regeneration closer to clinical implementation. These personalized therapies are poised to revolutionize the treatment of cardiovascular diseases and enhance the outcomes of patients with heart conditions as they continue to develop.

Conclusion

The field of human cardiac development and regeneration modeling offers a promising path towards innovative regenerative

therapies for cardiovascular diseases. By unraveling the complexities of cardiac development and exploring cutting-edge regenerative models, researchers are paving the way for more tailored and effective treatments in the realm of cardiovascular health. As advancements continue to unfold and translational research bridges the gap between bench and bedside, the potential for harnessing the regenerative capacity of the heart for clinical applications becomes increasingly tangible. Ultimately, the insights gained from studying cardiac development and regeneration have the power to revolutionize healthcare practices and improve the quality of life for patients with heart-related conditions. ■

References

1. Mathew P, Bordoni B. Embryology, Heart. [Updated 2023 Aug 14]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK537313/>
2. Christoffels V, Jensen B. Cardiac morphogenesis: Specification of the four-chambered heart. *Cold Spring Harb Perspect Biol* 2020; 12(10):a037143. DOI: <https://doi.org/10.1101/cshperspect.a037143>
3. Liu Y, Chen S, Zühlke L, Black GC, Choy MK, Li N, Keavney BD. Global birth prevalence of congenital heart defects 1970-2017: Updated systematic review and meta-analysis of 260 studies. *Int J Epidemiol* 2019; 48(2):455-463. DOI: <https://doi.org/10.1093/ije/dyz009>
4. Wu W, He J, Shao X. Incidence and mortality trend of congenital heart disease at the global, regional, and national level, 1990-2017. *Medicine (Baltimore)* 2020; 99(23):e20593. DOI: <https://doi.org/10.1097/MD.00000000000020593>
5. Hashimoto H, Olson EN, Bassel-Duby R. Therapeutic approaches for cardiac regeneration and repair. *Nat Rev Cardiol* 2018; 15(10):585-600. DOI: <https://doi.org/10.1038/s41569-018-0036-6>
6. Kloesel B, DiNardo JA, Body SC. Cardiac embryology and molecular mechanisms of congenital heart disease: A primer for anesthesiologists. *Anesth Analg* 2016; 123(3):551-569. DOI: <https://doi.org/10.1213/ANE.0000000000001451>
7. Anderson RH, Webb S, Brown NA, Lamers W, Moorman A. Development of the heart: (2) Septation of the atriums and ventricles. *Heart* 2003; 89(8):949-958. DOI: <https://doi.org/10.1136/heart.89.8.949>
8. Saxton A, Chaudhry R, Manna B. Anatomy, Thorax, Heart Right Coronary Arteries. [Updated 2023 Jul 24]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK537357/>
9. Hinton RB, Yutzey KE. Heart valve structure and function in development and disease. *Annu Rev Physiol* 2011; 73:29-46. DOI: <https://doi.org/10.1146/annurev-physiol-012110-142145>
10. Patra C, Zhang X, Brady MF. Physiology, Bundle of His. [Updated 2023 May 1]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK531498/>
11. Ripa R, George T, Shumway KR, et al. Physiology, Cardiac Muscle. [Updated 2023 Jul 30]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK572070/>
12. Tan CMJ, Lewandowski AJ. The transitional heart: From early embryonic and fetal development to neonatal life. *Fetal Diagn Ther* 2020; 47(5):373-386. DOI: <https://doi.org/10.1159/000501906>
13. Chaudhry R, Miao JH, Rehman A. Physiology, Cardiovascular. [Updated 2022 Oct 16]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK493197/>
14. Nesselmann C, Ma N, Bieback K, Wagner W, Ho A, Kontinen YT, Zhang H, Hinescu ME, Steinhoff G. Mesenchymal stem cells and cardiac repair. *J Cell Mol Med* 2008; 12(5B):1795-810. DOI: <https://doi.org/10.1111/j.1582-4934.2008.00457.x>. Erratum in: *J Cell Mol Med* 2008; 12(6B):2875.
15. Guo Y, Yu Y, Hu S, Chen Y, Shen Z. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. *Cell Death Dis* 2020; 11(5):349. DOI: <https://doi.org/10.1038/s41419-020-2542-9>
16. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. *Circ Res* 2015; 116(8):1413-1430. DOI: <https://doi.org/10.1161/CIRCRESAHA.116.303614>
17. Youssef AA, Ross EG, Bolli R, Pepine CJ, Leeper NJ, Yang PC. The promise and challenge of induced pluripotent stem cells for cardiovascular applications. *JACC Basic Transl Sci* 2016; 1(6):510-523. DOI:

<https://doi.org/10.1016/j.jacbts.2016.06.010>

18. Xiang M, Lu M, Quan J, Xu M, Meng D, Cui A, Li N, Liu Y, Lu P, Kang X, Wang X, Sun N, Zhao M, Liang Q, Le L, Wang X, Zhang J, Chen S. Direct in vivo application of induced pluripotent stem cells is feasible and can be safe. *Theranostics* 2019; 9(1):290-310. DOI: <https://doi.org/10.7150/thno.28671>
19. Rikhtegar R, Pezeshkian M, Dolati S, Safaie N, Afrasiabi Rad A, Mahdipour M, Nouri M, Jodati AR, Yousefi M. Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs, and skeletal myoblasts. *Biomed Pharmacother* 2019; 109:304-313. DOI: <https://doi.org/10.1016/j.biopha.2018.10.065>
20. Wang J, An M, Haubner BJ, Penninger JM. Cardiac regeneration: Options for repairing the injured heart. *Front Cardiovasc Med* 2023; 9:981982. DOI: <https://doi.org/10.3389/fcvm.2022.981982>
21. National Research Council (US) and Institute of Medicine (US) Committee on the Biological and Biomedical Applications of Stem Cell Research. *Stem Cells and the Future of Regenerative Medicine*. Washington (DC): National Academies Press (US); 2002. CHAPTER THREE, Embryonic Stem Cells. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK223690/>
22. du Pré BC, Doevendans PA, van Laake LW. Stem cells for cardiac repair: An introduction. *J Geriatr Cardiol* 2013; 10(2):186-97. DOI: <https://doi.org/10.3969/j.issn.1671-5411.2013.02.003>
23. Uygur A, Lee RT. Mechanisms of cardiac regeneration. *Dev Cell* 2016; 36(4):362-374. DOI: <https://doi.org/10.1016/j.devcel.2016.01.018>
24. Pourtaji A, Jahani V, Moallem SMH, Karimani A, Mohammadpour AH. Application of G-CSF in congestive heart failure treatment. *Curr Cardiol Rev* 2019; 15(2):83-90. DOI: <https://doi.org/10.2174/1573403X14666181031115118>
25. Bernitz JM, Daniel MG, Fstkhchyan YS, Moore K. Granulocyte colony-stimulating factor mobilizes dormant hematopoietic stem cells without proliferation in mice. *Blood* 2017; 129(14):1901-1912. DOI: <https://doi.org/10.1182/blood-2016-11-752923>
26. Carresi C, Scicchitano M, Scarano F, Macri R, Bosco F, Nucera S, Ruga S, Zito MC, Mollace R, Guarnieri L, Coppoletta AR, Gliozzi M, Musolino V, Maiuolo J, Palma E, Mollace V. The potential properties of natural compounds in cardiac stem cell activation: Their role in myocardial regeneration. *Nutrients* 2021; 13(1):275. DOI: <https://doi.org/10.3390/nu13010275>
27. Raynaud CM, Ahmad FS, Allouba M, Abou-Saleh H, Lui KO, Yacoub M. Reprogramming for cardiac regeneration. *Glob Cardiol Sci Pract* 2014; 2014(3):309-329. DOI: <https://doi.org/10.5339/gcsp.2014.44>
28. Mancuso A, Barone A, Cristiano MC, Cianflone E, Fresta M, Paolino D. Cardiac stem cell-loaded delivery systems: A new challenge for myocardial tissue regeneration. *Int J Mol Sci* 2020; 21(20):7701. DOI: <https://doi.org/10.3390/ijms21207701>
29. Sharma V, Dash SK, Govarthan K, Gahtori R, Negi N, Barani M, Tomar R, Chakraborty S, Mathapati S, Bishi DK, Negi P, Dua K, Singh SK, Gundamaraju R, Dey A, Ruokolainen J, Thakur VK, Kesari KK, Jha NK, Gupta PK, Ojha S. Recent advances in cardiac tissue engineering for the management of myocardium infarction. *Cells* 2021; 10(10):2538. DOI: <https://doi.org/10.3390/cells10102538>
30. Almeida SO, Skelton RJ, Adigopula S, Ardehali R. Arrhythmia in stem cell transplantation. *Card Electrophysiol Clin* 2015; 7(2):357-370. DOI: <https://doi.org/10.1016/j.ccep.2015.03.012>
31. Johnson RD, Lei M, McVey JH, Camelliti P. Human myofibroblasts increase the arrhythmogenic potential of human induced pluripotent stem cell-derived cardiomyocytes. *Cell Mol Life Sci* 2023; 80(9):276. DOI: <https://doi.org/10.1007/s00018-023-04924-3>
32. White SJ, Chong JJH. Growth factor therapy for cardiac repair: An overview of recent advances and future directions. *Biophys Rev* 2020; 12(4):805-815. DOI: <https://doi.org/10.1007/s12551-020-00734-0>
33. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. *Biochem Pharmacol* 2009; 78(6):539-552. DOI: <https://doi.org/10.1016/j.bcp.2009.04.029>
34. Soliman AM, Barreda DR. Acute inflammation in tissue healing. *Int J Mol Sci* 2022; 24(1):641. DOI: <https://doi.org/10.3390/ijms24010641>
35. Ucuzian AA, Gassman AA, East AT, Greisler HP. Molecular mediators of angiogenesis. *J Burn Care Res* 2010; 31(1):158-75. DOI: <https://doi.org/10.1097/BCR.0b013e3181c7ed82>
36. Smagul S, Kim Y, Smagulova A, Raziyeva K, Nurkesh A, Saparov A. Biomaterials loaded with growth factors/cytokines and stem cells for cardiac tissue regeneration. *Int J Mol Sci* 2020; 21(17):5952. DOI: <https://doi.org/10.3390/ijms21175952>
37. Khosravi F, Ahmadvand N, Bellusci S, Sauer H. The multifunctional contribution of FGF signaling to cardiac development, homeostasis, disease and repair. *Front Cell Dev Biol* 2021; 9:672935. DOI: <https://doi.org/10.3389/fcell.2021.672935>
38. Roacho-Pérez JA, Garza-Treviño EN, Moncada-Saucedo NK, Carriquiry-Chequer PA, Valencia-Gómez LE, Matthews ER, Gómez-Flores V, Simental-Mendía M, Delgado-Gonzalez P, Delgado-Gallegos JL, Padilla-Rivas GR, Islas JF. Artificial scaffolds in cardiac tissue engineering. *Life (Basel)* 2022; 12(8):1117. DOI: <https://doi.org/10.3390/life12081117>
39. Carroll KJ, Makarewich CA, McAnally J, Anderson DM, Zentilin L, Liu N, Giacca M, Bassel-Duby R, Olson EN. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. *Proc Natl Acad Sci U S A* 2016; 113(2):338-343. DOI: <https://doi.org/10.1073/pnas.1523918113>
40. Major RJ, Poss KD. Zebrafish heart regeneration as a model for cardiac tissue repair. *Drug Discov Today Dis Models* 2007; 4(4):219-225. DOI: <https://doi.org/10.1016/j.ddmod.2007.09.002>
41. Ryan R, Moysé BR, Richardson RJ. Zebrafish cardiac regeneration-looking beyond cardiomyocytes to a complex microenvironment. *Histochem Cell Biol* 2020; 154(5):533-548. DOI:

<https://doi.org/10.1007/s00418-020-01913-6>

42. Suzuki Y, Yeung AC, Ikeno F. The representative porcine model for human cardiovascular disease. *J Biomed Biotechnol* 2011; 2011:195483. DOI: <https://doi.org/10.1155/2011/195483>
43. von Bibra C, Hinkel R. Non-human primate studies for cardiomyocyte transplantation-ready for translation? *Front Pharmacol* 2024; 15:1408679. DOI: <https://doi.org/10.3389/fphar.2024.1408679>
44. Wang L, Hu D, Xu J, Hu J, Wang Y. Complex in vitro model: A transformative model in drug development and precision medicine. *Clin Transl Sci* 2023; 17(2):e13695. DOI: <https://doi.org/10.1111/cts.13695>
45. Khan A, Kumari P, Kumari N, Shaikh U, Ekhtor C, Halappa Nagaraj R, Yadav V, Khan AW, Lazarevic S, Bharati B, Lakshmipriya Vetrivendan G, Mulmi A, Mohamed H, Ullah A, Kadel B, Bellegarde SB, Rehman A. Biomimetic approaches in cardiac tissue engineering: Replicating the native heart microenvironment. *Cureus* 2023; 15(8):e43431. DOI: <https://doi.org/10.7759/cureus.43431>
46. Paik DT, Chandy M, Wu JC. Patient and disease-specific induced pluripotent stem cells for discovery of personalized cardiovascular drugs and therapeutics. *Pharmacol Rev* 2020; 72(1):320-342. DOI: <https://doi.org/10.1124/pr.116.013003>
47. Saini G, Segaran N, Mayer JL, Saini A, Albadawi H, Oklu R. Applications of 3D bioprinting in tissue engineering and regenerative medicine. *J Clin Med* 2021; 10(21):4966. DOI: <https://doi.org/10.3390/jcm10214966>
48. Tenreiro MF, Louro AF, Alves PM, Serra M. Next generation of heart regenerative therapies: Progress and promise of cardiac tissue engineering. *NPJ Regen Med* 2021; 6(1):30. DOI: <https://doi.org/10.1038/s41536-021-00140-4>
49. Välimäki MJ, Ruskoaho HJ. Targeting GATA4 for cardiac repair. *IUBMB Life* 2020; 72(1):68-79. DOI: <https://doi.org/10.1002/iub.2150>
50. Lai SL, Marín-Juez R, Stainier DYR. Immune responses in cardiac repair and regeneration: A comparative point of view. *Cell Mol Life Sci* 2019; 76(7):1365-1380. DOI: <https://doi.org/10.1007/s00018-018-2995-5>
51. Parmacek MS. Cardiac stem cells and progenitors: Developmental biology and therapeutic challenges. *Trans Am Clin Climatol Assoc* 2006; 117:239-255; discussion 255-256.
52. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. *Circ Res* 2017; 121(7):749-770. DOI: <https://doi.org/10.1161/CIRCRESAHA.117.311059>
53. Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, Rashidi M, Arshi A, Mokhtari-Farsani A. Comprehensive review of CRISPR-based gene editing: Mechanisms, challenges, and applications in cancer therapy. *Mol Cancer* 2024; 23(1):9. DOI: <https://doi.org/10.1186/s12943-023-01925-5>. Erratum in: *Mol Cancer*. 2024 Feb 27;23(1):43. DOI: <https://doi.org/10.1186/s12943-024-01961-9>
54. Lux CT, Scharenberg AM. Therapeutic gene editing safety and specificity. *Hematol Oncol Clin North Am* 2017; 31(5):787-795. DOI: <https://doi.org/10.1016/j.hoc.2017.05.002>
55. Chu P, Agapito-Tenfen SZ. Unintended genomic outcomes in current and next generation gm techniques: A systematic review. *Plants (Basel)* 2022; 11(21):2997. DOI: <https://doi.org/10.3390/plants11212997>
56. Xu M, Song J. Targeted therapy in cardiovascular disease: A precision therapy era. *Front Pharmacol* 2021; 12:623674. DOI: <https://doi.org/10.3389/fphar.2021.623674>. Erratum in: *Front Pharmacol* 2023; 14:1145460. DOI: <https://doi.org/10.3389/fphar.2023.1145460>
57. Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT. Stem cell-based therapy for human diseases. *Signal Transduct Target Ther* 2022; 7(1):272. DOI: <https://doi.org/10.1038/s41392-022-01134-4>
58. Rogozinski N, Yanez A, Bhoi R, Lee MY, Yang H. Current methods for fabricating 3D cardiac engineered constructs. *iScience* 2022; 25(5):104330. DOI: <https://doi.org/10.1016/j.isci.2022.104330>
59. Kim Y, Zharkinbekov Z, Sarsenova M, Yeltay G, Saparov A. Recent advances in gene therapy for cardiac tissue regeneration. *Int J Mol Sci* 2021; 22(17):9206. DOI: <https://doi.org/10.3390/ijms22179206>

Received: May 29, 2024 | Revised: June 27, 2024 | Accepted: July 08, 2024
